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One of the most important goals of asthma manage-
ment is to improve a patient's everyday functioning and
subjective well-being, often referred to as "quality of life".
Improvement in quality of life can be achieved through
improvement of respiratory function and reduction of
symptoms and exacerbations.  Whereas the impact of treat-
ment on respiratory functioning can be measured exactly,
the assessment of change in quality of life is often based
on the physician's intuition about the relevance of lung
function changes to a patient's daily functioning.  Until
recently, the measurement of quality of life by means
of questionnaires had not gained widespread acceptance
in asthma research.  A bibliography of quality of life
measures published in 1990 did not include a single
asthma-specific quality of life questionnaire [1].  How-
ever, quality of life measures are increasingly being pro-
posed as important efficacy endpoints, especially in studies
of drugs [2].  Quality of life monitoring is important, be-
cause it reflects patients' concerns and perceptions and
it can be one of the predictors of compliance.  Moreover,
the relatively weak correlations between lung function
and quality of life found in a number of earlier studies
[3–8], indicate that quality of life outcomes focus on
rather different aspects of a disease than the physiolog-
ical outcomes.  Together, these outcomes may give a
complete picture of a patient's health status.
Recently, a number of asthma-specific quality of life
measures have been proposed for use in clinical trials
Comparison of performance of four instruments in evaluating the effects of salmeterol
on asthma quality of life.  M.P.M.H. Rutten-van Mölken, F. Custers, E.K.A. Van Doorslaer,
C.C.M. Jansen, L. Heurman, F.P.V. Maesen, J.J. Smeets, A.M. Bommer, J.A.M. Raaijmakers.
ERS Journals Ltd 1995.
ABSTRACT:  Quality of life measures are increasingly used as important efficacy
endpoints in studies of drugs for asthma.  The purpose of this study was to assess
both the sensitivity to change and the construct validity of four different quality of
life instruments in patients with asthma.
In a double-blind, parallel group study, 120 moderate asthma patients, aged
between 18–70 yrs,  received either inhaled salmeterol 50 µg b.i.d. or inhaled salbu-
tamol 400 µg b.i.d. In addition to respiratory outcomes, quality of life was mea-
sured at a 6 weeks follow-up using: 1) Asthma Quality of Life Questionnaire (AQLQ);
2) Living With Asthma Questionnaire (LWAQ); 3) Sickness Impact Profile (SIP);
4) Rating Scale (RS); and Standard Gamble (SG) utilities.
Salmeterol led to significant improvements over salbutamol on virtually all clini-
cal outcomes.  Although all the quality of life instruments showed the same trend
in favour of salmeterol, only the AQLQ and RS utilities showed significantly greater
improvement on salmeterol than on salbutamol.  Except for the AQLQ, the corre-
lation between change in lung function and change in quality of life was generally
low.  Whereas, the AQLQ correlated well with the patient's overall assessment of
efficacy (r=0.64), the LWAQ, SIP and utilities failed to show such a correlation.
The AQLQ showed the best correlation with symptom scores.  The cross-sectional
correlation between the AQLQ and the LWAQ was 0.73, whereas the longitudinal
correlation was only 0.29.  The SG generally showed poor correlation with other
measures, including the RS.
In conclusion, patients given salmeterol showed a greater improvement in qual-
ity of life compared to patients given salbutamol.  Of the disease-specific question-
naires the Asthma Quality of Life Questionnaire was found to be more responsive
to change than the Living With Asthma Questionnaire and showed greater valid-
ity.  Of the generic instruments, the rating scale utilities were most responsive.  The
Standard Gamble showed poor correlation with other measures.
Eur Respir J., 1995, 8, 888–898.
*Dept of Health Economics, University of
Limburg, Maastricht, The Netherlands.
**Dept of Respiratory Medicine, De Wever
Hospital, Heerlen, The Netherlands. +Insti-
tute for Medical Technology Assessment,
Erasmus University Rotterdam, Rotterdam,
The Netherlands.  ++Glaxo B.V., Zeist, The
Netherlands.
Correspondence: 
M.P.M.H. Rutten-van Mölken
University of Limburg
Dept of Health Economics
P.O. Box 616 
6200 MD Maastricht
The Netherlands
Keywords:   Asthma
quality of life
reliability
salmeterol  
sensitivity to change
validity
Received:  April 29 1994
Accepted after revision February 25 1995
The study has been financially supported
by Glaxo B.V. The Netherlands.
COMPARING QUALITY OF LIFE IN ASTHMA
[9–14].  Assessing the measurement properties of these
instruments, such as validity, reliability and respon-
siveness,  is an ongoing process that has to be repeat-
ed in different countries, patient populations and treatment
settings.  Based on the current knowledge of measure-
ment properties, none of the recently developed asthma
quality of life questionnaires can be said to be superior
in particular circumstances.
In this study, we evaluated the measurement proper-
ties of the Dutch versions of four quality of life ques-
tionnaires in a clinical trial comparing salmeterol with
salbutamol.  Two of the questionnaires, the Living with
Asthma Questionnaire (LWAQ) and the Asthma Quality
of Life Questionnaire (AQLQ), were disease specific,
whereas the other two, the Sickness Impact Profile (SIP)
and the Patient Utilities, were generic.  The advantage of
incorporating both types of instruments into one study
is that we can make a detailed study of those aspects
of quality of life that are characteristic for asthma, as
well as a global assessment of overall quality of life.
Such an overall assessment enables the comparison of
results across different interventions for different diseases 
In the present study, we were primarily interested in
the responsiveness of the four questionnaires to clinical
improvements that were expected to result from salme-
terol compared to salbutamol.  Salmeterol is a new long-
acting β-agonist which, when compared to either placebo
or salbutamol, has been shown to increase clinic lung
function and both morning and evening peak flow, re-
duce diurnal variation in peak flow, and daytime and
nocturnal asthma symptoms and exacerbations, as well
as the need for additional bronchodilator rescue drugs
[15–18].  Furthermore, salmeterol has been shown to
improve the duration and quality of sleep [19].  This,
in turn, may be associated with better daytime func-
tioning and well-being.
All of these clinical effects of salmeterol may be
expected to improve quality of life.  Thus far, few stud-
ies have addressed this question. ULLMAN et al. [15]
found a nonsignificant trend towards a better sense of
well-being during salmeterol as compared to salbutamol
treatment.  A study by PALMER and HYLAND [20] showed
that the addition of salmeterol instead of placebo to a
patient's standard therapy improved the quality of life,
as measured with the LWAQ.  However, more than 50%
of the patients were excluded from this study because
they did not complete valid responses to the question-
naire.  JUNIPER et al. [21] showed that scores on the AQLQ
were significantly better on salmeterol than on a pla-
cebo or salbutamol.
In addition to the ability of the four quality of life
questionnaires to detect clinically important differen-
ces, we also looked into their longitudinal and cross-
sectional construct validity [22].  Both types of validity
were addressed, because the questionnaires can be used
to measure within-patient changes as well as to mea-
sure differences between patients with various degrees
of disease severity.  Assessing these psychometric prop-
erties may aid future selection of measures, assist in pri-
oritizing outcomes, and permit more accurate sample
size calculations.
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Methods
Patients
Subjects were out-patients with stable asthma, aged
18–70 yrs, who consented to participate in the study.  On
entering the study, they were required to have a forced
expiratory volume in one second (FEV1) of 50–70% of
predicted normal values, not having used bronchodilators
for at least 6 h previously.  The FEV1 had to increase by
at least 15% after inhalation of 400 µg salbutamol.  Pat-
ients were excluded if they had suffered a serious con-
comitant disease, an upper or lower respiratory tract
infection during the 6 weeks prior to the study, used a
booster course of oral steroids during the 6 weeks prior
to the study, were likely to change their concurrent medi-
cation for diseases other than asthma, or had a poor under-
standing of Dutch.  The use of theophyllines, other
β-agonists apart from study medication, β-blockers, methyl-
xanthines, or a booster course of corticosteroids was not
allowed.  All other maintenance drugs were continued at
constant dosage throughout the study.
Study design
The study had a double-blind, randomized, parallel
group design.  After a 2 week run-in period, 120 patients
eligible for treatment were randomized to receive 6
weeks of treatment with either salmeterol 50 µg b.i.d. or
salbutamol 400 µg b.i.d. Both drugs were administered
as dry powder via the diskhaler device.  Rescue salbuta-
mol in a diskhaler device was supplied for symptomatic
relief.  Patients were seen at the end of the run-in period,
after 3 weeks and 6 weeks of treatment, and 2 weeks after
cessation of treatment.  Quality of life measurements were
conducted at the end of the run-in period and after 6
weeks of treatment.  The study was approved by the
Medical Ethics Committee of the Wever Hospital.
Clinical outcome measures
FEV1 and forced vital capacity (FVC) were measured
at each clinic visit.  They were obtained from the best of
three measurements using a Sensor Medics Pulmograph.
Prior to these clinic measurements the patients withheld
inhaled bronchodilators for 12 h.  Reversibility was cal-
culated as the change in FEV1 after inhaling 400 µg
salbutamol divided by the prebronchodilator FEV1 and
expressed as a percentage.  Peak expiratory flow rate (PEFR)
measurements were obtained using the mini-Wright PEFR
meter each day on awakening and in the evening before
inhaling the study medication.  Patients kept a diary to
record the number of daytime and night-time rescue salbu-
tamol blisters (each blister contained 400 µg salbutamol),
and to record daytime and night-time asthma symptoms.
The daytime symptom score documented the frequency
and severity of symptoms on a scale from 0 (no symp-
toms during the day) to 5 (symptoms so severe that you
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could not go to work or perform normal daily activi-
ties).  The night-time symptom score ranged from 0 (no
symptoms during the night) to 4 (symptoms so severe
that you did not sleep at all).
An overall assessment of efficacy was obtained at
each clinic visit by asking the patients how their asth-
ma/breathing had been since the last visit, using a five
point response scale ranging from much improved to
much worse.
Quality of life instruments
All four quality of life measures used in this study
originate from the English language and were trans-
lated into Dutch.  The advantage of translating existing
measures over developing new measures is that it pro-
vides a basis for comparison of investigations of qual-
ity of life across different countries and cultures [23].
To a large extent, the translations were performed ac-
cording to recently published methods for good quality
translations [23, 24].
Asthma Quality of Life Questionnaire. The AQLQ was
developed by JUNIPER and co-workers [14].  The ques-
tionnaire is interviewer-administered and designed for
use in clinical trials involving adult asthma patients. It
contains 32 questions in four domains: activity limita-
tion (11 items); symptoms (12 items); emotional func-
tion (5 items); and environmental stimuli (4 items).  The
AQLQ is made up of questions which ask patients to
think about the last 2 weeks, and quantify, either in
terms of frequency, duration or amount, a number of
asthma-related problems.  At follow-up, patients are
shown the answers they have given at baseline.  The first
five questions in the activity limitation domain are
"patient-specific".  This means that at baseline each
patient is asked to state which five of his or her regular
activities are most troublesome because of asthma.  At
follow-up, the patient is again asked how severe the lim-
itation is in doing these same five activities.  Answers
to each of the 32 items can be scored on a 7 point scale,
ranging from 1, which indicates maximal impairment,
to 7, which indicates no impairment.  The results are
expressed as the mean score for each domain as well
as for overall quality of life.  The AQLQ was found to be
valid, reproducible, and responsive to change in time [8,
21, 25, 26].
The translation procedure of the AQLQ started with
forward translations by two independent translators,
who were aware of the objectives of the instruments and
the concepts involved.  When consensus had been reached
between the two translators and the researchers about
the forward translation, a backtranslation was performed
by a bilingual professional translator not involved in
health care research.  To check the face validity, the
questionnaires were completed by a number of patients
who were encouraged to comment on how they inter-
preted the questions.  If needed, alterations were made
in line with the suggestions.
Living with Asthma Questionnaire. The LWAQ was
developed by HYLAND et al. [10].  This questionnaire
was translated according to a similar procedure as the
AQLQ, which was extended by the use of several back-
translations.  The LWAQ consists of a list of 68 statements
covering 11 domains: social/leisure, sport, holidays,
sleep, work/other activities, colds, mobility, effects on
others, medication usage, sex, and dysphoric states and
attitudes.  Factor analysis has shown that the LWAQ
also covers two distinct constructs, which are labelled
"health knowledge" and "health appraisal" [27]. The first
construct, which contains 49 items, refers to the patient's
knowledge of functional limitation imposed by illness.
The second construct, which covers 19 items, refers to
the patient's evaluation of how much distress those lim-
itations cause.  The LWAQ does not ask patients to con-
sider a well-defined time period.  To compensate for the
tendency of patients to agree with a statement irrespec-
tive of its content, the LWAQ contains both positive and
negative statements.  Patients are asked to indicate for
each statement whether it is untrue, slightly true, very
true, or not applicable.  For negative statements, not ap-
plicable and untrue are scored 0, slightly true is scored 1,
and true is scored 2.  For positive items, not applicable and
very true are scored 0, slightly true is scored 1, and untrue
is scored 2.  Results can be expressed in an overall score,
scores for the 11 domain subscales and scores for the two
construct subscales.  Scores are based on a summation of
the patient's responses to all statements divided by the
number of valid statements (thus, compensating for state-
ments that are "not applicable" or missing) [20].  Thus, the
overall score and the subscores can range from 0 to 2.  The
lower the score, the better the quality of life. The LWAQ
has been shown to be reliable and valid [9, 10], and there
is some indication that it may be responsive to change
[27].
Sickness Impact Profile. In contrast to the two disease-
specific questionnaires described above, the SIP is a
comprehensive generic quality of life measure.  It was
developed by BERGNER et al. [28], and has been shown
to be reliable and valid.  A validated Dutch version of the
SIP is available [29].  The SIP measures health-related
dysfunction in 12 domains: ambulation, mobility, body
care and movement, social interaction, emotional behav-
iour, alertness behaviour, communication, work, eating,
sleep and rest, household management, and recreation and
pastimes.  It asks patients to consider their situation on
the day they complete the questionnaire.  The SIP pro-
vides summary scores for physical, psychosocial and
overall behavioural dysfunction, as well as separate scores
for the 12 domains.  Scores, which are calculated by addi-
tion of predetermined weights, range from 0 to l00, and
express the percentage of impairment.  The larger the
score the greater the impairment.  In this study, we applied
the original SIP item weights.  The SIP has been used in
many studies, including studies of patients with asthma
[6, 25, 26, 30, 31].
Patient utilities. The primary objective of the instruments
outlined above is to describe the (change in) quality of
life.  Utility measurement goes one step further by ex-
plicitly valuing the quality of life.  A utility is a single
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number on a scale ranging from perfect health, which
has a utility of 1, to death, which has a utility of 0. This
number represents the value or preference weight assigned
to a particular health state.  We have elicited utilities from
patients by means of a slightly adapted Dutch version
of the McMaster Utility Measurement Questionnaire
(MUMQ),  [32, 33].  This instrument was translated fol-
lowing exactly the same procedure as followed for the
AQLQ.  The back-translation of the MUMQ has been
published [34].  The patients are first asked to describe
their own health state over the past 2 weeks by indicat-
ing the level of dysfunction on six domains, i.e. physical
state and mobility, self-care, emotions, leisure activities,
pain or other complaints, and side-effects of treatment.
The actual valuation of their own health state is pre-
formed by means of rating scale and standard gamble
techniques [35].  The rating scale looks like a thermo-
meter with "perfect health" equal to 100 at the top and
"death" equal to 0 at the bottom.  Patients are asked to
place their own health state on that scale, in such a way
that it indicates how much better or worse their health
state is relative to death and perfect health.  In the stan-
dard gamble, patients are offered a choice between the
certainty of living in their current health state for the
rest of their life, or taking a gamble in which they have
chance p of returning to perfect health for the rest of
their life and chance l-p of dying immediately.  Probability
p is varied until patients are indifferent between the
gamble and living in their current health state.  At this
indifference point, the utility equals p.  For example, if
a patient is indifferent between continuing to live in
his current health state and a gamble offering 70%
chance of gaining perfect health and 30% chance of
dying, the utility or preference weight the patient assigns
to his own health state on the 0 to 1 scale is 0.7.
Analysis
Analyses of differences in baseline characteristics
between the two treatment groups were based on t-tests
for continuous data, and Mann-Whitney U-tests for ordi-
nal data.  Differences in proportions were analyzed using
χ2 tests.  A p-value equal to or less than 0.05 was con-
sidered statistically significant.  Diary card data were
summarized per patient by calculating means and stan-
dard deviations for the 2 week run-in period and the 6
week treatment period.
Responsiveness can be operationalized in three dif-
ferent ways.  Firstly, the ability of the questionnaires to
detect within-subject changes was compared by means
of paired t-tests.  Secondly, we compared the ability of
the questionnaires to detect differences in change bet-
ween the group receiving salmeterol and the group rec-
eiving salbutamol.  This was done by subjecting the change
scores to analysis of covariance (ANCOVA) with the
treatment group used as a factor and the baseline scores
used as covariates.  ANCOVA was also used to assess dif-
ferences in measures of lung function.  Further analyses
were performed to investigate whether the effect of treat-
ment was different between patients using corticosteroids
and patients not using corticosteroids.  Thirdly, we cal-
culated the effect sizes in the salmeterol and salbutamol
groups.  Effect size was calculated as the mean change
from baseline to follow-up in the salmeterol group divi-
ded by the pooled within-subject standard deviation of
change from both the salmeterol and salbutamol groups
[22, 36].
Cross-sectional construct validity was measured by
correlating quality of life scores at each visit with lung
function parameters and other quality of life scores.
Longitudinal construct validity was assessed by calcu-
lating correlations between within-subject changes in
quality of life scores and within-subject changes in lung
function parameters, symptom scores and other quality
of life scores.  The strength of the correlation was report-
ed using Spearman's rank correlation coefficients. The
correlation between change in quality of life and pat-
ient's overall assessment of efficacy expressed on a five
point scale was also seen as an indicator of longitudi-
nal construct validity.  The scores from the overall as-
sessment were reversed, so that a higher score means a
better efficacy.  The patient's overall assessment of effi-
cacy was seen as a reference measure of whether or not
a patient had changed.  If the change in quality of life
scores reflects this overall assessment of change (i.e. a
strong correlation), this is seen as evidence of longitudi-
nal validity.
Results
Patients
After randomization, one of the 120 patients had to be
excluded because his understanding of the Dutch lan-
guage was too poor to complete the questionnaires.  Eight
of the remaining 119 patients did not complete the 6
week follow-up measurement.  Three of these patients (one
salmeterol and two salbutamol) dropped out because of
pulmonary problems.  The pulmonary problems of the
two patients receiving salbutamol were so serious that
they required hospitalization.  Two patients (one salme-
terol and one salbutamol) dropped out because of other
illnesses, and two patients (one salmeterol and one sal-
butamol) dropped out due to family circumstances (e.g.
death of a close relative).  One patient receiving salme-
terol was no longer willing to participate.  Another four
patients (two salmeterol and two salbutamol) were not
included in the analysis because of protocol violations
(they were given antibiotics to treat respiratory infec-
tions).  Thus, the analyses were performed on 107 patients,
53 receiving salmeterol and 54 receiving salbutamol.
The baseline characteristics of the patients who were
not included in the analysis did not differ from those
who completed the study.  Table 1 shows no statistically
significant differences between the treatments groups
at baseline.  Also, no significant differences were found
on social indicators, such as marital status, educational
level, income and employment, except for the fact that a
smaller percentage of the patients in the salmeterol group
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pectively).  The percentage of days without any symp-
toms was significantly higher for salmeterol than for
salbutamol (63 versus 48%; p=0.039), but the percent-
age of nights without awakenings was not significantly
different between the groups (80 versus 70%; p=0.108).
Asthma-related adverse events and pharmacologically
predictable adverse events occurred at the same rate in
both treatment groups.  After 3 weeks of treatment the
patients' overall assessments of efficacy clearly favoured
salmeterol (table 3).  After 6 weeks of treatment no fur-
ther changes in the patients' overall assessments were
found.
Responsiveness
Table 4 shows that the AQLQ, the LWAQ and the rat-
ing scale utilities were highly responsive to the within-
patient improvements in the salmeterol group.  These
measures also showed some within-patient improve-
ment in the salbutamol group.  Only the standard gamble
utilities showed a within-patient deterioration of quality
had children (64 vs 84%; p=0.024).  No differences were
found between the groups on baseline quality of life
scores.
Clinical outcome measures
Table 2 shows that salmeterol led to significant improve-
ments over salbutamol on all respiratory outcomes, ex-
cept for PEFR in the evening.  No significant difference in
these improvements was observed between patients tak-
ing corticosteroids and those not taking corticosteroids.
Thus, an interaction between corticosteroid use and type
of bronchodilator was not present.  The mean use of sup-
plemental salbutamol during daytime was significantly
lower for salmeterol than for salbutamol (0.64 versus
1.24 blisters·day-1; p=0.013).  The additional salbutamol
use during the night was not significantly different
between the groups (0.13 versus 0.25 blisters·day-1;
p=0.076). The mean daytime and night-time symptom
scores were very low and not significantly different bet-
ween the two treatment groups (p=0.08 and p=0.67, res-
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Table 1.  –  Baseline characteristics by treatment group
Treatment groups
Salmeterol Salbutamol p=value#
n=53 n=54
Age  yrs* 51 (15) 55 (13) 0.103
Sex  M/F 27/26 33/21 0.289
Age of asthma onset  yrs* 31 (20) 33 (20) 0.695
FEV1 % pred* 59 (7) 59 (7) 0.958
PEFR prebronchodilator   L·s* 4.0 (1.2) 4.2 (1.4) 0.473
PEFR postbronchodilator  L·s-1* 5.3 (1.7) 5.1 (1.5) 0.546
Reversibility  %+ 27 (17, 35) 22 (17, 31) 0.154
Using steroids  n
Inhaled 37 33 0.077
Oral 4 0
Both 3 4
Asthma Quality of Life Quest.* 5.55 (1.01) 5.62 (0.84) 0.702
Living with Asthma Quest* 0.78 (0.36) 0.77 (0.31) 0.963
Sickness Impact Profile* 6.99 (6.43) 9.03 (7.56) 0.137
Utilities*
Rating scale 69.91 (13.95) 67.13 (17.44) 0.366
Standard gamble 0.87 (0.13) 0.87 (0.16) 0.760
*: data are presented as mean and SD in parenthesis. +: median and (quartiles).  M: male; F: female; FEV1: forced expir-
atory volume in one second;  PEFR: peak expiratory flow rate;  % pred: percentage of predicted value;  Quest.: Questionnaire.
#: p-value, salmeterol vs salbutamol.
Table 2.  –  Effectiveness of the two treatments in terms of lung function by treatment group
Mean change in lung function
95%
Salmeterol Salbutamol ∆(salm - salb) CI of diff. p-value#
PEFR  a.m.  L·min-1 +32.9 +8.6 24.3 8.94–39.6 0.002
PEFR  p.m.  L·min-1 +16.8 +4.3 12.5 -1.2–26.1 0.073
FEV1 % pred +9.3 +1.7 7.5 3.2–11.9 0.001
FVC  L +0.32 +0.04 0.27 0.10–0.44 0.002
Reversibility  % -16.1 -7.3 -8.8 -12.8–4.8 <0.001
FVC: forced vital capacity;  salm: salmeterol;  salb: salbutamol;  ∆: difference; 95% CI: 95% confidence interval. #: salmeterol
vs salbutamol.
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of life in the salbutamol group.  This deterioration was
not found in any of the other quality of life measures.
Although all the questionnaires revealed the same trend
in favour of salmeterol, only the AQLQ and the rating
scale utilities showed a statistically significant higher
improvement in quality of life on salmeterol than on
salbutamol.  The overall AQLQ score and the domain
scores for activity and symptoms showed a significantly
greater improvement on salmeterol.  The activity domain
of the AQLQ was found to be most responsive, and the
emotional domain was the least responsive to change.
The overall LWAQ score and its construct subscores did
not show a significant difference between the groups.
However, the table does not show the finding that 2 of
its 11 domains, sport and sex, did show a difference in
favour of salmeterol.  The mean difference between
the groups as regards change in the dimension of sport
was 0.27 (95% confidence interval (95% CI) 0.09–0.44;
p=0.003) and the mean difference for change in the
dimension of sex was 0.24 (95% CI 0.05–0.42; p=0.012).
No significant interaction effect between treatment and
the use of corticosteroids was found for any of the qual-
ity of life outcomes.
Table 5 relates the change in the mean score in the
salmeterol group to the within-subject standard deviation
of change in both the salmeterol and salbutamol groups.
The effect sizes that result from this analysis showed
the AQLQ to be most responsive, followed by the LWAQ
and rating scale utilities.
Cross-sectional validity
Cross-sectional construct validity correlations are given
in table 6.  In general, the association between quality
of life measures and lung function measures was low.
The SIP correlated significantly with all lung function
measures except reversibility.  The LWAQ and the SIP
correlated better with the FVC, and the AQLQ correlat-
ed better with reversibility, than the other quality of life
measures.
All quality of life questionnaires, except for the stan-
dard gamble utilities, correlated significantly with both
daytime and night-time symptom scores.  This correla-
tion was considerably higher for the AQLQ than for the
other questionnaires.
The correlations among quality of life questionnaires
were much higher than the correlations between quality
of life and lung function.  The correlation between the
two disease-specific quality of life measures was strong.
The SIP correlates well with the LWAQ and rating scale
utilities.  Standard gamble utilities showed weak corre-
lations with the other quality of life measures.
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Table 3.  –  Patients' overall assessment of efficacy after
3 weeks of treatment
Salmeterol Salbutamol
Asthma:
Much improved 9 3
Improved 22 12
Equal 21 34
Worse 1 4
Much worse 0 0
Mann-Whitney test: p=0.001.
Table 4.  –  Responsiveness to changes within subjects and differences in changes between salmeterol
(n=53) and salbutamol (n=54)
Change in Quality of Life
Salmeterol Salbutamol Diff. 95% CI p-value#
(salm - salb) of diff.
AQLQ +0.49*** +0.27*** 0.22 0.03–0.42 0.022
Activities +0.57*** +0.22* 0.35 0.14–0.56 0.002
Symptoms +0.58*** +0.33** 0.25 -0.001–0.49 0.051
Environment +0.44*** +0.22* 0.22 -0.04–0.48 0.100
Emotions +0.18* +0.17* 0.01 -0.19–0.20 0.960
LWAQ -0.12*** -0.09* 0.03 -0.04–0.09 0.425
Health knowledge -0.13*** -0.08** 0.05 -0.02–0.12 0.146
Health appraisal -0.06** -0.10 0.04 -0.12–0.03 0.290
SIP -1.59 -0.93 0.66 -1.11–2.43 0.463
Physical -0.83 -0.20 0.62 -0.73–2.00 0.363
Psychosocial -2.82** -1.91* 0.91 -1.35–3.16 0.429
Utilities
Rating Scale +7.35*** +4.08** 3.27 0.08–6.46 0.045
Standard Gamble +0.008 -0.034* 0.042 -0.005–0.09 0.077
Covariance analysis: improvement is indicated by a plus for the AQLQ and the Utilities, and by a minus for the LWAQ and
the SIP.  AQLQ: Asthma Quality of Life Questionnaire;  LWAQ: Living with Ashma Questionnaire; SIP: Sickness Impact
Profile;  For further abbreviations see legend to table 2.  Within-patient changes;  *: p≤0.05; **: p≤0.01; ***: p≤0.001.  #: p-
value, salmeterol vs salbutamol.
Longitudinal validity
Longitudinal construct validity correlations are given
in table 7.  Of all quality of life measures, the change in
AQLQ correlates best with the change in lung function.
The longitudinal correlations between these two meas-
ures are stronger than the cross-sectional correlations.
The other quality of life measures show hardly any cor-
relation with lung function.
The longitudinal correlation with both daytime and
night-time symptom score is best for the AQLQ, fol-
lowed by the rating scale utilities.  The change in LWAQ
correlates with change in daytime symptom score only.
The relatively high correlation between the AQLQ and
the patients' overall assessments of efficacy indicates
that the patients' perceptions of change were indeed reflec-
ted in changes in the quality of life as measured with
the AQLQ.  The other quality of life measures did not
reflect the patients' global assessments of efficacy.
The change in AQLQ shows significant correlation
with change in all other quality of life measures.  This longi-
tudinal correlation was strongest between the AQLQ and
the rating scale utilities.  The change in LWAQ correlates
with the change AQLQ and the change in SIP, but not
with the change in utilities.  The correlation between the
two utility measures is nonsignificant.
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Table 5.  –  Effect sizes in salmeterol group by quality of life instrument
Quality of life Within-subject Pooled within-subject Effect size##
instrument ∆salm SD of change#
AQLQ 0.492 0.600 0.820
Activities 0.573 0.666 0.860
Symptoms 0.581 0.803 0.723
Environment 0.438 0.797 0.550
Emotions 0.176 0.583 0.302
LWAQ 0.118 0.170 0.694
Health knowledge 0.130 0.208 0.625
Health appraisal 0.064 0.192 0.333
SIP 1.585 4.956 0.320
Physical 0.827 3.950 0.209
Psychosocial 2.815 6.648 0.423
Utilities
Rating Scale 7.345 10.381 0.708
Standard Gamble 0.008 0.161 0.050
∆slm: change in salmeterol.  #: SD ∆salm+salb; ##: ∆salm/SD ∆salm+salb.  For further abbreviations see
legend to tables 2 and 4.
Table 6.  Cross-sectional validity: Spearman's rank correlation coefficients
Quality of Life
AQLQ LWAQ SIP RS utilities SG utilities
Lung function
PEFR a.m. 0.02 -0.13 -0.16* 0.13 0.05
PEFR p.m. -0.03# -0.09 -0.17* 0.11 0.06
FEV1 % pred 0.12 -0.15 -0.17* 0.22** -0.04#
FVC  L 0.13 -0.26** -0.29** 0.10 0.06
Reversibility  % -0.28** 0.17* 0.02 -0.09 0.04#
Symptoms
Daytime score -0.59** 0.42** +0.39** -0.26* -0.17
Night-time score -0.70** 0.42** +0.38** -0.33** -0.21
Quality of Life
AQLQ -0.73** -0.48** 0.47** 0.19*
LWAQ 0.56** -0.43** -0.13
SIP -0.59** -0.15
RS utilities 0.17*
RS: Rating Scale; SG: Standard Gamble.  For further abbreviations see legend to tables 1, 2 and 4.  *:
p≤0.01; **: p≤0.001; #: paradoxical direction.
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Discussion
Whether a quality of life questionnaire is suitable for
use in clinical trials depends largely on how well it detects
treatment-related changes in the impact of a disease on
quality of life.  Of all the quality of life measures we used
in this study, only the AQLQ and the rating scale utili-
ties reflected the greater improvement that was found in
virtually all clinical outcome measures on treatment with
salmeterol as compared to salbutamol.  The LWAQ domain
scores for sport and sex also showed a significant differ-
ence in favour of salmeterol.  However, despite the pres-
ence of clear clinical differences, the overall LWAQ and
its two construct scores failed to detect a difference in
quality of life between the treatment groups.
The AQLQ was found to be the most sensitive to improve-
ments in health status.  The greater responsiveness of the
AQLQ may result from "informed" administration [37],
i.e. that patients read the answers they had given at base-
line just before answering the questions at follow-up.
This "informed answering" is a part of the administra-
tion procedure prescribed for this questionnaire, and con-
trasts with the procedure for the other questionnaires.
The activity domain of the AQLQ was particularly
highly responsive.  The responsiveness may be increased
because 5 of the 8 items in this domain are "patient-
specific", which means that patients themselves indicate
which five most important activities should form the
items. Thus, the activity domain focuses on what really
matters to a patient.  The most frequently identified indi-
vidual activities that were impaired because of asthma
were housework (e.g. vacuuming, scrubbing the floor)
which was mentioned by 37% of the patients, walking
uphill or upstairs (33%), sleeping (25%), hurrying (25%),
exercising (e.g. running, football, ballet) (22%) and cycling
(20%).  The disadvantage of using individualized items
may be that comparing the activity scores between patients
is somewhat difficult, since they relate to different activ-
ities.  Moreover, individualization is not a prerequisite for
responsivenes: a recent study showed that the nonindi-
vidualized St. Georges Respiratory Questionnaire Impact
score was able to detect a difference between nedocromil
sodium and placebo, even though the clinical improve-
ments due to this drug seemed to be less than the improve-
ments achieved by salmeterol in our trial [31].  The
emotional and environmental domains of the AQLQ
were less responsive than the activities and symptom
domains.  The environmental domain examines how en-
vironmental stimuli, such as smoke, weather, perfumes
and smells, affect the patient's asthma.  Probably, this is
unlikely to be influenced to any great extent by drugs
that primarily aim at bronchodilation.  The emotional do-
main addresses topics such as concern, frustration and
fear, which may be highly related to a patient's psycho-
logical disposition, and is unlikely to change in 6 weeks.
This explains why the developers of the LWAQ pre-
dicted that the health appraisal construct of the LWAQ
would be less responsive to change over time caused by
drug treatment than the health knowledge construct [38].
Since the presence of problems is more closely related
to morbidity, the patient's knowledge of these problems
is expected to be more sensitive to changes in morbid-
ity than the patient's emotional appraisal of these prob-
lems, which is more closely related to personality.  This
hypothesis is confirmed in our study.  It also suggests
that for a quality of life instrument to be highly respon-
sive, it should focus on functional limitation more than
on emotional dysfunction.
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Table 7.  –  Longitudinal construct validity: Spearman's rank correlation coefficients between change values
Change in Quality of Life
Change in AQLQ LWAQ SIP RS utilities SG utilities
Lung function
PEFR  a.m. -0.36** -0.04 -0.19 0.19 0.23*
PEFR p.m. 0.35** -0.20 -0.28* 0.08 0.16
FEV1 % pred 0.32** -0.05 -0.11 0.19 0.09
FVC 0.28* -0.05 -0.12 0.21 0.24*
Reversibility  % -0.21 -0.02# 0.01 -0.12 -0.03
Symptoms
Daytime score 0.51** -0.24* -0.20 0.24* 0.08
Night-time score 0.54** -0.06 -0.04 0.23* 0.14
Overall assessment of efficacy ~ 0.64** -0.20 -0.29 0.24 0.20
Quality of Life
AQLQ -0.29* -0.31** 0.36** 0.29**
LWAQ 0.31** -0.11 -0.09
SIP -0.17 -0.18
RS utilities 0.16
RS: Rating Scale; SG: Standard Gamble.  For further abbreviations see legends to table 1, 2 and 4.  *: p≤0.01; **: p≤0.001;
#: paradoxical direction; ~: the patient's overall assessment of efficacy is not a change score.
Although the health knowledge construct is more respon-
sive than the health appraisal construct, it is not as respon-
sive as the activity domain of the AQLQ, even though
it covers a greater range of activity restriction. Along with
the patient-specific questions of the AQLQ, this may be
due to the process through which the items were reduced.
The item reduction process in constructing the LWAQ
was based on factor analysis, whereas the item reduction
process of the AQLQ was based on patient responses.  Thus,
the latter includes only those activities which were fre-
quently reported and judged important [39].
Of the two utility measurement techniques used in our
study, only the rating scale measured a significantly grea-
ter improvement on salmeterol than on salbutamol.  It
was more responsive to change than the standard gam-
ble.  Utilities elicited via the standard gamble technique
were the only outcomes that showed a deterioration in
the salbutamol group.  All other measures showed a trend
indicating an improvement of quality of life in both
groups, but a greater improvement in the salmeterol
than in the salbutamol group.  This deterioration was not
a result of outlier values.  It was mainly due to the fact
that salbutamol patients who stated in the overall assess-
ment that they had not changed showed a significantly
larger reduction in mean utility than salmeterol patients
who stated they had not changed.  We do not have a
good explanation for this.
That the observed trend was not significant in a num-
ber of quality of life measures does not necessarily imply
that there are no real differences in the domains of these
questionnaires.  Since salmeterol is clinically effective,
it could have led to an increased level of activity as a
result of which the burden of symptoms is also increased
[40]. Furthermore, the extra effects of salmeterol over
salbutamol may be camouflaged by the higher use of res-
cue salbutamol (especially during the day) in patients
given salbutamol.
This difference in the use of rescue salbutamol may
also explain why there seems to be no improvement in night-
time asthma due to salmeterol.  Since, the percentage of
nights without awakenings did not show a significant dif-
ference between the two groups.  However, during both
the day and the night, patients receiving salbutamol used
more supplemental salbutamol than patients receiving
salmeterol, although only the daytime use was signifi-
cantly different between the groups.  Furthermore, in both
treatment groups the symptom scores were very low at
baseline, thus leaving little room for improvement.
It is known that generic quality of life measures, such
as the SIP are usually less responsive to small changes
than disease-specific measures.  Although the SIP showed
the overall trend for greater improvement in salmeterol
than in salbutamol, it failed to identify a significant dif-
ference between patients receiving salmeterol and pat-
ients receiving salbutamol.  The latter is similar to the
result of a recent study in mild to moderate asthma
patients, in which nedocromil sodium led to significant
improvements in asthma severity, night-time asthma, day-
time bronchodilator use and the St George's Respiratory
Questionnaire Impacts score, but not in the SIP score
[31].  Nevertheless, the use of generic quality of life
measures has the advantage that it allows comparisons
across diseases and patient populations, which is of inter-
est especially when the results of a study are presented
to policy makers.  Inclusion of generic quality of life mea-
sures in addition to disease-specific measures is useful
in providing a broader range of domains in which changes
may be detected.  A new drug, such as salmeterol, may
have unanticipated effects on quality of life that are not
detected by disease-specific questionnaires.  However, the
SIP did not detect any such effects.  Our patients' SIP
scores were skewed towards the less impaired end of the
scale, thus leaving little room for improvement.  The same
is true for the standard gamble, the mean score of which
was already 0.87 at baseline.  Patients with the best pos-
sible score can still have substantial quality of life impair-
ment.  But improvements in these patients simply cannot
be detected by the instrument.  Such a ceiling effect [41]
decreases the responsiveness of an instrument.
Assessing the statistical significance of changes in qual-
ity of life measures is relatively easy, but a meaningful
interpretation of the magnitude of the significant changes
that have been found is difficult.  This is because we have
not yet had the opportunity to gain wide experience with
these instruments, and are still unfamiliar with their units
of change.  By relating changes in AQLQ scores to patients'
overall assessments of change, JUNIPER and co-workers
[42] demonstrated that a within-subject change of 0.5
both for the overall and the AQLQ domain scores can
be seen as the minimal important difference.  This is the
smallest difference which patients perceive as beneficial.
Thus, in our study, the change in overall AQLQ score
and in the activities and symptoms domain scores with-
in the salmeterol group can be judged clinically relevant.
No such studies of the minimal important differences
have been carried out for the other instruments.
Not only patients given salmeterol, but also patients
given salbutamol show some improvement in respiratory
function and quality of life after 6 weeks of treatment.
These quality of life improvements were large enough
to be detected by the AQLQ, the LWAQ, and the rating
scale utilities.  Thus, salbutamol appears to have a pos-
itive effect on quality of life as well.  To some extent this
effect may result from patients receiving increased atten-
tion in a clinical trial situation compared to routine clin-
ical practice.  Furthermore, the knowledge that the effects
of treatment will be carefully measured may have led to
an increased compliance of patients with the drug ther-
apy.
In the literature, evidence of responsiveness is seen
both as a distinct property of a quality of life measure
and as an indication of a measure's validity [43].  In the
absence of a gold standard for quality of life validity can
be assessed by examining the correlations between the
questionnaires and measures of respiratory function or
symptoms, as these are assumed to influence physical
functioning and perhaps other aspects of quality of life.
This kind of validity is referred to as construct validity.
With respect to the longitudinal correlation with lung
function and symptom scores, the AQLQ again per-
formed best.  The AQLQ showed relatively high corre-
lation both with daytime and night-time symptom scores.
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The changes in LWAQ, SIP and utilities hardly showed
any correlation with changes in lung function parame-
ters.  These three instruments also failed to correlate with
the patients' overall assessments of efficacy.  A number of
correlations had paradoxical directions.  However, these
correlations were all nonsignificant.
Construct validity can also be assessed by comparing
the correlations among various quality of life measures.
The correlations among quality of life measures were much
higher than the correlations between quality of life mea-
sures and respiratory function.  For example, the cross-
sectional correlation between the LWAQ and the AQLQ
was 0.73.  This might be expected given the large degree
of overlap in the content of the items which comprise
the scales.  However, longitudinally, the correlation bet-
ween the LWAQ and the AQLQ was only 0.29.  The
change in AQLQ correlates better with the change in rat-
ing scale utilities than with the change in LWAQ.
Construct validity evaluation showed that rating scale
utilities correlated better with symptom scores than stan-
dard gamble utilities.  It also showed that rating scale util-
ities correlated better with other quality of life measures
than standard gamble utilities.  The correlation between
the two types of utilities was weak.  Either the standard
gamble measures largely different aspects of health - in
which case our validity concept is not valid - or the stan-
dard gamble has indeed lower construct validity.  It may
be that it chiefly measures patients' risk behaviour, since
patients are asked to value their health states under risk
conditions, whereas with the rating scale health states
are valued under certainty.
In summary, the results of this study indicate that sal-
meterol tends to have a more favourable effect on qual-
ity of life than salbutamol.  The AQLQ and the rating scale
utilities were found to be sufficiently responsive to detect
the clinically important changes due to the use of sal-
meterol, whereas the LWAQ, the SIP and the standard
gamble utilities were not.  Of the two disease-specific
instruments, the AQLQ was found to be more valid than
the LWAQ.  Of the generic instruments, the validity of
the standard gamble was worst.
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